Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- M +10.5%, NICE +6.4%, MMS +5.3%, CPA +4.9%, DOLE +4.9%, BRC +4.5%, BORR +4.3%, AEG +3.9%, TTEK +3%, BERY +2.9%, FMC +1.5%, HI +1.3%, JJSF +1.1%, SNEX +0.8%
Other news:
- CRSP +5.4% (CRISPR Therapeutics and Vertex Pharma (VRTX) announce authorization of the first CRISPR/Cas9 Gene-Edited Therapy CASGEVY (exagamglogene autotemcel) by the UK MHRA)
- GRWG +4.2% (CEO disclosed the purchase of 496000 shares at $1.91 - $2.37 worth nearly $1 mln)
- QDEL +3.2% (weighing sale of Transfusion Medicine business according to Bloomberg Law)
- ADMA +2.9% (Receives FDA Approval for its Tenth Plasma Collection Center Located in Laurel MD)
- ARDX +2.8% (XPHOZAH granted Orphan Drug Designation by FDA)
- SWTX +1.9% (announces positive topline results from the phase 2b reneu trial of mirdametinib in NF1-PN)
- PRMW +1.5% (names new CEO)
- VRTX +1% (CRISPR Therapeutics and Vertex Pharma (VRTX) announce authorization of the first CRISPR/Cas9 Gene-Edited Therapy CASGEVY (exagamglogene autotemcel) by the UK MHRA)
Analyst comments:
- COMM +4.8% (upgraded to Mkt Perform from Underperform at Raymond James)
- GT +2% (upgraded to Buy from Hold at Deutsche Bank)
- CTLT +1.8% (upgraded to Outperform from Neutral at Robert Baird)
- BWA +1.7% (upgraded to Buy from Neutral at Guggenheim)
- IBP +1.2% (upgraded to Buy from Neutral at Goldman)